title: [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].
abstract: OBJECTIVE
  To compare the health-related quality of life (HRQL) in the patients with reflux esophagitis (RE) and non-erosive reflux disease (NERD) treated with rabeprazole in the multi-center open study.
  
  
  METHODS
  All patients were treated with rebaprazole (10 mg, bid, ac) for eight weeks from Dec. 2002 to June 2003. 74 patients with RE; and 37 patients with NERD defined as negative endoscopic finding, the Demeester scores of 24 h pH monitoring of esophagus > 14.27 and reflux symptoms score > 6, were enrolled in. The impacts on HRQL (SF-36 questionnaire) and GERD-HRQL were assessed before and after therapy.
  
  
  RESULTS
  At baseline, HRQL in NERD patients was impaired greater than in RE patients. After therapy, the symptoms were improved significantly in both groups. The quality of life was improved in 7 subscales in RE patients. However it was much lower in NERD patients. The scale of GERD-HRQL decreased significantly in RE patients than in NERD patients.
  
  
  CONCLUSIONS
  NERD causes a more significant impairment in the quality of life than RE, which can be attenuated partly after 8 w rabeprazole therapy, unlike the satisfactory results favored in RE. Further research is needed to more completely understand the value of rabeprazole therapy for NERD.
authors.affiliation: Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
authors.forename: Xiao-hong
authors.initials: XH
authors.lastname: Liu
authors.forename: Mei-yun
authors.initials: MY
authors.lastname: Ke
authors.forename: Zhi-qiang
authors.initials: ZQ
authors.lastname: Song
authors.forename: Jin-yan
authors.initials: JY
authors.lastname: Luo
authors.forename: Yao-zong
authors.initials: YZ
authors.lastname: Yuan
authors.forename: Xiao-hua
authors.initials: XH
authors.lastname: Hou
authors.forename: You-ling
authors.initials: YL
authors.lastname: Zhu
authors.forename: Jing
authors.initials: J
authors.lastname: Sun
authors.forename: Hui
authors.initials: H
authors.lastname: Zha
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011788:Quality of Life; D064750:Rabeprazole; D011795:Surveys and Questionnaires
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D064750:Rabeprazole; D009853:Omeprazole